PMID- 33915693
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210502
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 13
IP  - 7
DP  - 2021 Apr 1
TI  - Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced 
      Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A 
      Retrospective Cohort Study.
LID - 10.3390/cancers13071623 [doi]
LID - 1623
AB  - Background: Checkpoint inhibitors are a standard of care in the treatment of 
      advanced renal cell carcinoma (RCC) and urothelial carcinoma (UC). Patients with 
      these tumors often suffer from concomitant chronic kidney disease (CKD). Limited 
      data are available on the efficacy and toxicity of checkpoint inhibitors in 
      patients with CKD. Methods: We retrospectively analyzed 126 patients who received 
      checkpoint inhibitors for RCC (n = 85) or UC (n = 41) and analyzed the frequency 
      of treatment- and immune-related adverse events (AEs). We performed a 
      multivariate analysis to determine progression-free survival (PFS) and overall 
      survival (OS). Results: A total of 38.9% of patients had CKD. Frequencies of 
      general AEs (49.0% in CKD vs. 48.1%, p > 0.99999) and immune-related AEs (28.6 
      vs. 24.7%, p >/= 0.9999) did not significantly differ between the groups. There was 
      no difference in PFS for patients with RCC or UC and CKD or without CKD (RCC: 
      6.81 vs. 7.54 months, HR 1.000 (95%CI 0.548-01.822), p = 0.999; UC:2.33 vs. 3.67 
      months, HR 01.492 (95%CI 0.686-3.247), p = 0.431). CKD appeared to be a potential 
      effect modifier for OS in both RCC and UC (RCC: NR vs. 23.9 months, HR 0.502 
      (95%CI 0.219-1.152), p = 0.104; UC:18.84 vs. 15.42 months, HR 0.656 (95%CI 
      0.296-1.454), p = 0.299). Conclusions: Checkpoint inhibitor treatment in our 
      cohort of patients with CKD was as safe and efficient as in the cohort of 
      patients without CKD.
FAU - Seydel, Florian
AU  - Seydel F
AD  - Department of Nephrology, University Hospital Heidelberg, 69120 Heidelberg, 
      Germany.
FAU - Delecluse, Susanne
AU  - Delecluse S
AD  - Department of Nephrology, University Hospital Heidelberg, 69120 Heidelberg, 
      Germany.
AD  - German Center for Infection Research (DZIF), 69120 Heidelberg, Germany.
AD  - German Cancer Research Centre (DKFZ) Unit F100, 69120 Heidelberg, Germany.
FAU - Zeier, Martin
AU  - Zeier M
AD  - Department of Nephrology, University Hospital Heidelberg, 69120 Heidelberg, 
      Germany.
FAU - Holland-Letz, Tim
AU  - Holland-Letz T
AD  - German Cancer Research Centre (DKFZ) Unit C060, 69120 Heidelberg, Germany.
FAU - Haag, Georg Martin
AU  - Haag GM
AD  - Department of Medical Oncology, National Center of Tumor Diseases (NCT), 
      University Hospital Heidelberg, 69120 Heidelberg, Germany.
FAU - Berger, Anne Katrin
AU  - Berger AK
AD  - Department of Medical Oncology, National Center of Tumor Diseases (NCT), 
      University Hospital Heidelberg, 69120 Heidelberg, Germany.
FAU - Grun, Barbara Christine
AU  - Grun BC
AD  - Department of Medical Oncology, National Center of Tumor Diseases (NCT), 
      University Hospital Heidelberg, 69120 Heidelberg, Germany.
FAU - Bougatf, Nina
AU  - Bougatf N
AUID- ORCID: 0000-0002-0718-7360
AD  - Cancer Registry, National Center of Tumor Diseases (NCT), University Hospital 
      Heidelberg, 69120 Heidelberg, Germany.
FAU - Hohenfellner, Markus
AU  - Hohenfellner M
AD  - Department of Urology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
FAU - Duensing, Stefan
AU  - Duensing S
AD  - Department of Urology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
FAU - Jager, Dirk
AU  - Jager D
AD  - Department of Medical Oncology, National Center of Tumor Diseases (NCT), 
      University Hospital Heidelberg, 69120 Heidelberg, Germany.
FAU - Zschabitz, Stefanie
AU  - Zschabitz S
AD  - Department of Medical Oncology, National Center of Tumor Diseases (NCT), 
      University Hospital Heidelberg, 69120 Heidelberg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20210401
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC8036307
OTO - NOTNLM
OT  - checkpoint inhibitor
OT  - chronic kidney disease
OT  - renal cell carcinoma
OT  - urothelial carcinoma
COIS- The authors have declared that no competing interest exists.
EDAT- 2021/05/01 06:00
MHDA- 2021/05/01 06:01
PMCR- 2021/04/01
CRDT- 2021/04/30 01:00
PHST- 2021/01/31 00:00 [received]
PHST- 2021/03/24 00:00 [revised]
PHST- 2021/03/26 00:00 [accepted]
PHST- 2021/04/30 01:00 [entrez]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2021/05/01 06:01 [medline]
PHST- 2021/04/01 00:00 [pmc-release]
AID - cancers13071623 [pii]
AID - cancers-13-01623 [pii]
AID - 10.3390/cancers13071623 [doi]
PST - epublish
SO  - Cancers (Basel). 2021 Apr 1;13(7):1623. doi: 10.3390/cancers13071623.